Scientists finally reveal how this Alzheimer’s drug really works
Why it matters: Understanding lecanemab’s Fc‑driven action could accelerate safer Alzheimer’s treatments for millions.
- Lecanemab (Leqembi) works via its Fc fragment that activates microglia to clear amyloid plaques (per VIB/KU Leuven, Nature Neuroscience).
- Microglia are reprogrammed by the Fc anchor to become efficient plaque‑removers, confirming their central role in anti‑amyloid therapy (study’s key insight).
- Previous theories suggesting plaque clearance without Fc involvement are challenged, aligning the field toward immune‑engagement mechanisms (contrasting earlier speculation).
- Future drug design can now target Fc‑mediated pathways to boost efficacy and reduce side effects, promising better outcomes for the 55 million Alzheimer’s patients worldwide (implication).
Researchers from VIB and KU Leuven have pinpointed the Fc fragment of lecanemab as the trigger that enlists microglia to clear amyloid plaques, finally explaining how the FDA‑approved Alzheimer’s drug works and opening a roadmap for safer, more effective immunotherapies.
